600285.SS
600285.SS
CNE000001501
HENAN LINGRUI PHARMACEUTICAL
Loading chart...

Company Profile

Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Medical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, nutritional supplements, and anesthesiology. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules. The company also engages in industrial and real estate investment; technology research and development; ecological agriculture; and high-tech activities. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is headquartered in Xinyang, China.

Related stocks

000756.SZ
000756.SZ • China
XINHUA PHARM
14.81 CNY
1.54B USD 1Y -5.5%
300026.SZ
300026.SZ • China
CHASE SUN PHARM.
3.32 CNY
1.49B USD 1Y -10.8%
002675.SZ
002675.SZ • China
DONGCHENG BIOCHEM
13.89 CNY
1.71B USD 1Y -7%
600420.SS
600420.SS • China
SHANGHAI SHYNDEC PHARMACEUTICAL
8.51 CNY
1.71B USD 1Y -20.2%
002755.SZ
002755.SZ • China
ASK PHARM
13.34 CNY
1.85B USD 1Y -32.7%
002020.SZ
002020.SZ • China
JINGXIN
11.87 CNY
1.53B USD 1Y -41.5%
603538.SS
603538.SS • China
NINGBO MENOVO PHARMACEUTICAL CO
28.45 CNY
1.45B USD 1Y +80%
002550.SZ
002550.SZ • China
QIANHONG BIO-PHARMA
6.52 CNY
1.25B USD 1Y -28.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
35.1% p.a.
Max Drawdown (5Y)
-41.2%
Sharpe Ratio (5Y)
0.26
Beta Factor
-0.02
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (35.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -48.0% in the extended horizon.
ende